FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Related Research units
Abstract
Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 29 |
| ISSN | 0732-183X |
| Publication status | Published - 2011 |
| pubmed | 21911727 |
|---|
